BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 31686762)

  • 1. Ultrasound-based techniques for the diagnosis of liver steatosis.
    Ferraioli G; Soares Monteiro LB
    World J Gastroenterol; 2019 Oct; 25(40):6053-6062. PubMed ID: 31686762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis.
    Hsu PK; Wu LS; Su WW; Su PY; Chen YY; Hsu YC; Yen HH; Wu CL
    PLoS One; 2021; 16(10):e0254892. PubMed ID: 34653177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease.
    Paige JS; Bernstein GS; Heba E; Costa EAC; Fereirra M; Wolfson T; Gamst AC; Valasek MA; Lin GY; Han A; Erdman JW; O'Brien WD; Andre MP; Loomba R; Sirlin CB
    AJR Am J Roentgenol; 2017 May; 208(5):W168-W177. PubMed ID: 28267360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens).
    Ferraioli G
    J Med Ultrason (2001); 2021 Oct; 48(4):489-495. PubMed ID: 34132934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort.
    Beyer C; Hutton C; Andersson A; Imajo K; Nakajima A; Kiker D; Banerjee R; Dennis A
    PLoS One; 2021; 16(4):e0249491. PubMed ID: 33793651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective comparison of three ultrasound-based techniques in quantitative diagnosis of hepatic steatosis in NAFLD.
    Zhu Y; Yin H; Zhou D; Zhao Q; Wang K; Fan Y; Chen K; Han H; Xu H
    Abdom Radiol (NY); 2024 Jan; 49(1):81-92. PubMed ID: 37950767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?
    Xavier SA; Monteiro SO; Arieira CM; Castro FD; Magalhães JT; Leite SM; Marinho CM; Cotter JB
    Mol Genet Metab; 2021 Mar; 132(3):204-209. PubMed ID: 33558081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter.
    Ferraioli G; Calcaterra V; Lissandrin R; Guazzotti M; Maiocchi L; Tinelli C; De Silvestri A; Regalbuto C; Pelizzo G; Larizza D; Filice C
    BMC Gastroenterol; 2017 May; 17(1):61. PubMed ID: 28472948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
    Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance.
    Ozturk A; Grajo JR; Gee MS; Benjamin A; Zubajlo RE; Thomenius KE; Anthony BW; Samir AE; Dhyani M
    Ultrasound Med Biol; 2018 Dec; 44(12):2461-2475. PubMed ID: 30232020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
    Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
    World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.
    Ahn JM; Paik YH; Min SY; Cho JY; Sohn W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut Liver; 2016 Mar; 10(2):295-302. PubMed ID: 26347511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.